Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||9.01%||12.95||0.7%||$905.25m|
|GILD||Gilead Sciences, Inc.||0.13%||68.15||1.0%||$461.62m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.92%||194.80||1.9%||$449.28m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.61%||528.75||2.7%||$364.34m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.00%||181.65||2.0%||$341.36m|
|EXAS||EXACT Sciences Corp.||2.56%||125.01||18.1%||$192.21m|
|BNGO||Bionano Genomics, Inc.||3.17%||7.82||0.0%||$186.15m|
|ONTX||Onconova Therapeutics, Inc.||6.93%||7.56||1.8%||$181.22m|
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firmâ€™s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.